

## Special Issue

# Renal Cell Carcinoma: From Diagnosis to Identification of Novel Therapeutic Targets and Minimally Invasive Treatments

### Message from the Guest Editors

Renal cell carcinoma (RCC) is the most frequent malignancy affecting the adult kidney and the twelfth most common cancer. The pathophysiology of RCC is complex and arises from a combination of gene mutations (i.e., VHL, PBR1, SETD2, BAP1, etc.) in addition to other factors such as diabetes, obesity, smoking, and hypertension. In the early stages, the disease is frequently asymptomatic and incidentally diagnosed by imaging, having a good prognosis; conversely, RCC has a high mortality rate in advanced phases, due to poor responses to radiotherapy and chemotherapy. The progressive introduction of high-throughput technologies and recent studies of molecular and genomic profiling have shed new light on the pathophysiology of RCC. Moreover, in recent years, there has been a growing interest in identifying tumor markers not only for diagnostic purposes but also to improve the predictive power of clinical and pathological parameters. This Special Issue of *Diagnostics* aims to collect studies on minimally invasive treatment and translational research for the management and diagnosis of renal cell carcinoma (RCC). This is the joint Special Issue both in *Biomedicines* and *Diagnostics*.

---

### Guest Editors

Dr. Matteo Ferro  
Prof. Dr. Andrea Minervini  
Prof. Dr. Alessandro Antonelli  
Dr. Angelo Porreca  
Prof. Dr. Giuseppe Lucarelli  
Prof. Dr. Michele Battaglia  
et al.

---

### Deadline for manuscript submissions

closed (31 August 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/85902](https://mdpi.com/si/85902)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).